In November 2017, Asana Medical, Inc. announced that they had formally changed their name to Regentys, as a more distinctive representation of their business model and underlying regenerative medicine technology.

Regentys Named Finalist!

June 28, 2018

Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) have selected 11 Patient Entrepreneur finalists who will compete in the “Empowering Patients: An Innovation Challenge” to earn the Lyfebulb and UnitedHealth Group Innovation Award.

Read More →

Regentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis Treatment

Feb. 14, 2018

Regentys (formerly Asana Medical, Inc.), a regenerative medicine company, today announced it will partner with Cook Biotech Inc., a world leader in cost-effective, advanced tissue-repair products, to develop a novel treatment for ulcerative colitis.

Read More →

Regentys Names Dr. John F. Howes Vice President of Clinical and Regulatory Affairs

Jan. 9, 2018

Company Continues to Add Distinguished Medical Experts as Focus Pivots to First-In-Human Clinical Trials of its Novel, Regenerative Medicine Solution for Ulcerative Colitis.

Read More →

Regentys Appoints Dr. Steven D. Wexner Chief Medical Officer

Dec. 7, 2017

Regentys (formerly Asana Medical, Inc.) has named Dr. Steven D. Wexner as its Chief Medical Officer (“CMO”). Dr. Wexner has been a member of the Regentys Medical Advisory Board since January 2014.

Read More →

Asana Medical, Inc. Announces Corporate Name Change to Regentys

Nov. 28, 2017

MIAMI LAKES, FL – November 28, 2017 -- Asana Medical, Inc., ("Asana"), a regenerative medicine company developing a novel treatment for Ulcerative Colitis (“UC”), is pleased to announce that it has changed its corporate name to Regentys (“Regentys”, the “Company”). The change, which also includes a new corporate logo and branding platform, reflects the Company’s continuing vision and development of its regenerative medicine technologies portfolio, and its lead product, ExtraCellular Matrix Hydrogel (“ECMH”).

Read More →